Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.62 as of 2026-10-06T21:40:49.277Z.
Consensus retrieved: 2026-10-06T09:10:06.772Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:40:49.277Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a02320b8c72f41f256db809c519e542ea793cb4b76494a25863e3696123995a0
Forward PE Ratio (16.62) = Dated Quote Price ($15.69) / Consensus Forward EPS ($0.94)
FORWARD PE RATIO
16.62
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-15.85%
vs the sector median at left
Aurinia Pharmaceuticals Inc.
Market Cap
$2.02B
Forward PE Ratio
16.62
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.02B | 16.62 |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 20.15 |
| Vericel Corporation (VCEL)vs › | $2.05B | 74.94 |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 24.71 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 57.10 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A |
| Alvotech (ALVO)vs › | $2.08B | N/A |
Trailing P/E
6.8
reported TTM EPS
Forward P/E
16.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.94 implies -59.0% EPS decline vs the reported trailing $2.29.
At the dated quote price of $15.69, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.94 | $0.89 – $1.08 | 4 | 16.6x |
| 2027-12-31 | $1.18 | $1.15 – $1.20 | 4 | 13.3x |
| 2028-12-31 | $1.44 | $0.52 – $2.67 | 5 | 10.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
